Gastrointestinal Cancer Clinical Trial
Official title:
A Feasibility Study of Acupuncture for the Treatment of Postoperative Ileus After Gastrointestinal Surgery
NCT number | NCT04713241 |
Other study ID # | CASE3220 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | January 2022 |
Est. completion date | March 2023 |
Verified date | March 2022 |
Source | Case Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to learn if electro-acupuncture is a feasible treatment option for postoperative ileus after abdominal surgery. The second goal of this study is to evaluate the time to resolution of postoperative ileus after receiving electro-acupuncture treatments.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 2023 |
Est. primary completion date | March 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - Must have the ability to understand and sign a written informed consent document, and be willing to follow protocol requirements - Diagnosis of gastrointestinal cancer - Bowel resection was performed via an open or laparoscopic approach - Diagnosis of POI defined as one or more of the following criteria: 1) return to NPO status after initial attempts at oral diet, and/or 2) need for placement of nasogastric tube after surgery. - Willingness to comply with all study interventions of acupuncture Exclusion Criteria: - Active Infection at or near the acupuncture site or systemic infection (e.g. sepsis) - Physical deformities that could interfere with accurate acupuncture and point location - Concurrent use of other alternative medicines such as herbal agents and high dose vitamins and minerals - Known coagulopathy or taking heparin (including low molecular weight heparin) at full anti-coagulation doses (prophylaxis is allowed) or Coumadin at any dose. Patients on aspirin or non-steroidal anti-inflammatories or other antiplatelet medicines will be allowed to participate - Platelets <50 H K/UL in the past 30 days - White Blood Cells (WBCs) <3.0 K/UL or Absolute Neutrophil Count (ANC) <1500 K/UL in the past 30 days - INR >5 in the past 30 days - Liver failure defined as liver function test >5x upper limit of normal - Implanted electrical device such as a cardiac pacemaker, insulin pump or pain pump - Mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry - Previous acupuncture treatment for any indications within 30 days of enrollment - Currently pregnant - Grade III lymphedema/lymphedema considered severe by the treating clinician - Chronic daily opioid use prior to admission - Enrollment in another surgical clinical trial |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Case Comprehensive Cancer Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility as measured by acceptance rate of participation in study | Feasibility of acupuncture in study group as measured by acceptance rate of participation in study. Acceptance rate greater than 50% of patients being willing to participate will be considered feasible | An average of 1 day post-treatment | |
Secondary | Time of ability to tolerate oral diet (liquid and solid food in hours) | Time to resolution of Postoperative ileus (POI) as measured by time of ability to tolerate oral diet (liquid and solid food in hours)
Reported in mean, standard deviation as well as the five number summary including the 25th, 50th, and 75th percentiles, the minimum and maximum values |
An average of 1 day post-treatment | |
Secondary | Nasogastric tube (NG TB) output | NG tube output, defined as volume of fluid collected from the NG TB
Reported in mean, standard deviation as well as the five number summary including the 25th, 50th, and 75th percentiles, the minimum and maximum values |
An average of 1 day post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Not yet recruiting |
NCT05044312 -
Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis
|
N/A | |
Active, not recruiting |
NCT05053191 -
Advancing Nursing Practices in Hospital Oncology Care
|
N/A | |
Completed |
NCT03611309 -
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
|
N/A | |
Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06398314 -
Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors
|
N/A | |
Withdrawn |
NCT04030624 -
Remote Electronic Patient Monitoring in Gastrointestinal Cancer
|
N/A | |
Completed |
NCT02140593 -
The Laparotomy Study
|
Phase 4 | |
Completed |
NCT02222259 -
A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients
|
N/A | |
Active, not recruiting |
NCT00716209 -
Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers
|
N/A | |
Recruiting |
NCT01484444 -
Biomarker Analysis of Gastrointestinal Cancer
|
N/A | |
Completed |
NCT02130427 -
A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
|
N/A | |
Active, not recruiting |
NCT00710632 -
Screening to Predict Weight Loss in Patients With Cancer
|
N/A | |
Completed |
NCT00094965 -
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
|
Phase 2 | |
Terminated |
NCT04077372 -
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05429866 -
Immunological Variables Associated to ICI Toxicity in Cancer Patients
|
Phase 2 | |
Recruiting |
NCT05226221 -
Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
|
||
Recruiting |
NCT03286348 -
Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer
|
N/A |